Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

by Michele De Tursi, Mario Alberto Occhipinti, Vincenzo Di Noia, Pamela Pizzutilo, Giada Targato, Simona Scodes, Fabrizio Tabbò, Fausto Petrelli
Published 2020-07-01

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer

by Giuseppe Bronte, Maurizio Puccetti, Elisabetta Petracci, Lorenza Landi, Paola Cravero, Simona Scodes, Paola Ulivi, Sara Ravaioli, Maria Maddalena Tumedei, Marco Angelo Burgio, Federico Cappuzzo, Angelo Delmonte, Lucio Crinò, Sara Bravaccini
Published 2021-05-01